'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have so far trailed the benchmark in 2024.

In late afternoon trade today, shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock are down 1.5% at $288.17. That's right about where the stock started in 2024 and is well behind the 7% year to date gains posted by the ASX 200.

Over the past 12 months, however, the biotech stock has outpaced the benchmark, gaining 25% compared to the 21% gain achieved by the ASX 200.

CSL shares also trade on an unfranked trailing dividend yield of 1.4%.

And according to Bell Potter Securities' Christopher Watt (courtesy of The Bull), they present an "appealing buying opportunity".

Time to buy CSL shares?

"CSL is a global biotechnology company. Its medicines treat haemophilia and immune deficiencies. It makes vaccines to prevent influenza," explains Watt, who has a buy rating on CSL shares. "The company provides products to patients in more than 100 countries."

As for why the ASX 200 biotech stock is one to buy today, Watt said:

CSL is a consistent performer. It generated total revenue of US$14.8 billion in fiscal year 2024, an increase of 11% on the prior corresponding period. Reported net profit after tax of US$2.642 billion was up 20%.

The shares were recently trading at a discount and present an appealing buying opportunity, in our view.

What's been happening with the ASX 200 biotech stock?

CSL shares were in the spotlight on 13 August when the company reported its FY 2024 results.

Driving the strong growth metrics Watt highlighted above, CSL's Behring business achieved a 14% year on year increase in total revenue to US$10.61 billion. The company's immunoglobulin sales reached US$5.67 billion, up 20% from FY 2023.

And helping support profits, CSL's plasma collection costs continued to decline over the year.

The ASX 200 biotech stock also provided some bullish guidance for FY 2025, though some market analysts were expecting even more.

Commenting on what might impact CSL shares in the year ahead, CEO Paul McKenzie said on the day:

For FY 2025, revenue growth is anticipated to be approximately 5% to  7% over FY 2024 at constant currency. CSL's NPATA [net profit after tax and amortisation] for FY 2025 is anticipated to be in the range of approximately $3.2 billion to $3.3 billion at constant currency, representing growth over FY 2024 of approximately 10% to 13%.

Over the medium term, CSL is in a strong position to continue to deliver annualised double-digit earnings growth.

CSL reaffirmed this guidance at the company's AGM earlier this week.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Healthcare Shares

ResMed shares jump 8% on stellar start to FY25

This high-quality company continues to deliver the goods.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

A 'golden era' is coming for these ASX healthcare shares

Here's why Blackwattle Partners sees tailwinds ahead for one particular category of healthcare shares.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is rising on big FDA news

Some big news is giving this stock a major lift on Thursday.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Healthcare Shares

Why it's a big day for CSL shares today

This biotechnology company is holding its annual R&D event today.

Read more »

Lab worker puts hands in the air and dances around
Share Gainers

$6,000 invested in this ASX 200 stock 5 years ago is now worth $84,000!

ASX 200 investors who bought this growth stock five years ago have achieved remarkable gains.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Buy and hold this ASX dividend legend up 900% over 25 years

This stock has delivered healthy returns for shareholders.

Read more »